XML 115 R62.htm IDEA: XBRL DOCUMENT v3.24.3
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES    
SCHEDULE OF NET LOSS PER SHARE

The following table summarizes the Company’s net loss per share (in thousands, except share and per share amounts):

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2024

    

2023

    

2024

    

2023

Numerator:

 

  

 

  

 

  

 

  

Net loss

$

(16,237)

$

(19,563)

$

(64,198)

$

(55,108)

Net loss attributable to common stockholders

$

(16,237)

$

(19,563)

$

(64,198)

$

(55,108)

Denominator:

 

  

 

  

 

  

 

  

Weighted-average common stock outstanding, basic and diluted

 

28,863,327

 

27,640,542

 

28,572,338

 

25,872,118

Net loss per share, basic and diluted

$

(0.56)

$

(0.71)

$

(2.25)

$

(2.13)

The following table summarizes the Company’s net loss per share:

Year Ended December 31, 

    

2023

    

2022

Numerator:

 

  

 

  

Net loss

$

(75,521)

$

(51,511)

Net loss available to common stockholders

$

(75,521)

$

(51,511)

Denominator:

 

  

 

  

Weighted-average common stock outstanding, basic and diluted

 

26,331,630

 

24,472,104

Net loss per share, basic and diluted

$

(2.87)

$

(2.10)

SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES NOT INCLUDED IN THE CALCULATION OF DILUTED NET LOSS PER SHARE

Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):

As of September 30, 

    

2024

    

2023

Options to purchase common stock

 

3,714,104

 

5,236,832

Unvested restricted stock units

25,754

 

3,714,104

 

5,262,586

Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would have had an anti-dilutive effect are as follows (in common stock equivalent shares):

As of December 31, 

    

2023

    

2022

Options to purchase common stock

 

5,230,344

 

4,110,219

Unvested restricted stock units

21,968

28,881

 

5,252,312

 

4,139,100